Related Experiment Video
Updated: Jul 20, 2026
12:37
Modeling Colitis-Associated Cancer with Azoxymethane (AOM) and Dextran Sulfate Sodium (DSS)
Published on: September 11, 2012
Review article: aminosalicylates for distal colitis.
P Gionchetti1, F Rizzello, C Morselli
1Department of Internal Medicine, University of Bologna, Bologna, Italy. paolo@med.unibo.it
Alimentary Pharmacology & Therapeutics
|September 12, 2006
Summary
Topical aminosalicylate therapy is effective for ulcerative colitis, especially for distal inflammation. Formulations like suppositories, enemas, and foams deliver drugs directly to the inflamed site, improving remission rates.
Area of Science:
- Gastroenterology
- Pharmacology
Background:
- Ulcerative colitis (UC) often involves distal inflammation, making topical treatments viable.
- Topical therapies offer targeted drug delivery, minimizing systemic absorption and side effects.
Purpose of the Study:
- To evaluate the efficacy of topical aminosalicylate therapy in ulcerative colitis.
- To compare different topical formulations and dosages for treating UC.
Main Methods:
- Review of aminosalicylate formulations including suppositories, enemas, foams, and gels.
- Comparison of treatment outcomes for various topical and oral aminosalicylate therapies.
Main Results:
- Topical aminosalicylates are highly effective for distal UC, with suppositories ideal for proctitis and distal sigmoiditis.
- A 1g Pentasa suppository daily showed faster remission and better tolerance than 500mg twice daily.
- Enemas, foams, and gels are suitable for proctosigmoiditis and left-sided colitis.
- Combination therapy (oral and topical) is effective for refractory patients and superior for remission maintenance.
Conclusions:
- Topical aminosalicylates are a cornerstone treatment for ulcerative colitis, particularly for distal disease.
- Optimal formulation choice depends on the extent of colonic inflammation.
- Combination therapy enhances remission maintenance compared to monotherapy.
Related Concept Videos
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:20Inflammatory Bowel Disease II: Ulcerative Colitis
Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...
01:21Inflammatory Bowel Disease V: Surgical Management
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD: